Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AZRX

AzurRx BioPharma (AZRX) Stock Price, News & Analysis

AzurRx BioPharma logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

Key Stats

Today's Range
$0.39
$0.42
50-Day Range
$2.40
$41.00
52-Week Range
$3.36
$26.30
Volume
27,416 shs
Average Volume
628,703 shs
Market Capitalization
$3.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AZRX Stock News Headlines

Entero Therapeutics Inc (ENTO)
YS YS Biopharma Co., Ltd.
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
See More Headlines

AZRX Stock Analysis - Frequently Asked Questions

AzurRx BioPharma's stock reverse split on the morning of Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZRX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-32,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.76) per share

Miscellaneous

Free Float
8,645,000
Market Cap
$3.74 million
Optionable
Not Optionable
Beta
1.51
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:AZRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners